EX-99.2 3 catx-ex99_2.htm EX-99.2

Slide 1

Corporate Presentation

Slide 2

 

Slide 3

Developing the next generation of targeted therapies

Slide 4

Higher potency payloads with cancer-specific targeting

Slide 5

 

Slide 6

Upcoming data milestones

Slide 7

Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 8

 

Slide 9

Perspective’s Innovative Platform

Slide 10

Perspective’s radiopharmaceutical platform optimized for a broader therapeutic window

Slide 11

Perspective’s proprietary chelator has been optimized for lead-based RPTs

Slide 12

 

Slide 13

 

Slide 14

Proposed mechanism of action for 212Pb

Slide 15

Rationale for synergy with immune checkpoint inhibitors

Slide 16

 

Slide 17

Supply Chain and Manufacturing Infrastructure

Slide 18

On-demand order fulfillment at regional sites to deliver finished products

Slide 19

 

Slide 20

Neuroendocrine Tumors: VMT-⍺-NET

Slide 21

 

Slide 22

 

Slide 23

 

Slide 24

Trial design: [212Pb]VMT-⍺-NET Phase 1/2a for PRRT naïve neuroendocrine tumors

Slide 25

Compelling anti-tumor activity

Slide 26

Durable disease control across all doses

Slide 27

Signal of sustained anti-tumor activity

Slide 28

Best-in-class safety profile1

Slide 29

Select adverse events of special interest

Slide 30

Mild and generally transient blood creatinine increase

Slide 31

[212Pb]VMT-α-NET was well-tolerated and demonstrated compelling anti-tumor activity

Slide 32

Melanoma Program: VMT01/02

Slide 33

 

Slide 34

 

Slide 35

 

Slide 36

 

Slide 37

Trial design: [212Pb]VMT01 Phase 1/2a for metastatic melanoma

Slide 38

 

Slide 39

Treatment emergent adverse events (all grades, occurring in ≥ 2 patients)

Slide 40

 

Slide 41

 

Slide 42

 

Slide 43

 

Slide 44

 

Slide 45

PSV359 is active against FAP-α expression on tumor and on stroma

Slide 46

 

Slide 47

 

Slide 48

Trial design: [212Pb]PSV359 Phase 1/2a trial

Slide 49

 

Slide 50

General Corporate Information

Slide 51

 

Slide 52

 

Slide 53

 

Slide 54

 

Slide 55

Abbreviations

Slide 56

APPENDIX

Slide 57

 

Slide 58

NETs trials

Slide 59

Potential for differentiated profile based on molecular design

Slide 60

Durable disease control across all doses

Slide 61

Refractory metastatic melanoma trials

Slide 62

Daily production at regional sites ensures supply of ready-to-administer product

Slide 63

 

Slide 64

 

Slide 65

 

Slide 66

 

Slide 67

 

Slide 68

Perspective’s pre-targeting platform